Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Colorado: - Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
- Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
- Saint Francis Cancer Center — Colorado Springs, Colorado
- CommonSpirit Cancer Center Mercy — Durango, Colorado
- Mercy Medical Center — Durango, Colorado
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxalipl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06662786
Sites in Colorado: - Rocky Mountain Cancer Centers — Denver, Colorado
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
Sponsor: Incyte Corporation
NCT ID: NCT07284849
Sites in Colorado: - Sarah Cannon Research Institute Scri Oncology Partners — Aurora, Colorado
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Sites in Colorado: - University of Colorado Denver Anschultz Medical Campus — Aurora, Colorado
- Rocky Mountain Cancer Centers — Denver, Colorado
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
Phase 3 Recruiting Industry
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06997497
Sites in Colorado: - University of Colorado Health - Harmony-Cancer Care and Hematology - Ft. Collins ( Site 0087) — Fort Collins, Colorado
- Rocky Mountain Cancer Centers (RMCC) ( Site 8000) — Lone Tree, Colorado
Phase 3 Recruiting Industry
This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall surv…
Sponsor: EMD Serono Research & Development Institute, Inc.
NCT ID: NCT07549412
Sites in Colorado: - Rocky Mountain Cancer Centers, LLP- Aurora — Lone Tree, Colorado
Phase 3 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard…
Sponsor: AbbVie
NCT ID: NCT07525206
Sites in Colorado: - Rocky Mountain Cancer Centers - Aurora /ID# 280112 — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Colorado: - Local Institution - 1003 — Aurora, Colorado
- Local Institution - 2103 — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Colorado: - Rocky Mountain Cancer Center — Denver, Colorado
- Sarah Cannon Research Institute at HealthONE — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Colorado: - Rocky Mountain Cancer Center — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…
Sponsor: Merus B.V.
NCT ID: NCT03526835
Sites in Colorado: - Rocky Mountain Cancer Centers — Lone Tree, Colorado
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Colorado: - University of Colorado - Aurora Cancer Center — Aurora, Colorado
Phase 2 Recruiting Academic/Other
This is an open-label multicenter, single-arm Phase II study of Fruquintinib in combination with FOLFIRI (leucovorin calcium (folinic acid), fluorouracil, and irinotecan) in participants with metastatic colorectal cancer (mCRC). The main g…
Sponsor: SCRI Development Innovations, LLC
NCT ID: NCT07011576
Sites in Colorado: - Rocky Mountain Cancer Center - Primary — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the bo…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06428409
Sites in Colorado: - University of Colorado Anschutz Medical Campus ( Site 0299) — Aurora, Colorado
- University of Colorado Anschutz Medical Campus ( Site 0325) — Aurora, Colorado
- University of Colorado Anschutz Medical Campus ( Site 0326) — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Sponsor: GV20 Therapeutics
NCT ID: NCT05669430
Sites in Colorado: - HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uv…
Sponsor: IDEAYA Biosciences
NCT ID: NCT03947385
Sites in Colorado: - SCRI - Denver — Denver, Colorado
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Pa…
Sponsor: Phanes Therapeutics
NCT ID: NCT05482893
Sites in Colorado: - Sarah Cannon Research Institute (SCRI) — Denver, Colorado
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial studies the side effects and best dose of pidnarulex when given together with cemiplimab and to see how well it works in treating patients with microsatellite stable (MSS) colorectal cancer (CRC) that does not respond…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07147231
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
Phase 2 Recruiting Industry
This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable …
Sponsor: Kahr Bio Australia Pty Ltd
NCT ID: NCT07235293
Sites in Colorado: - University of Colorado Hospital- Anschutz Cancer Center Pavillion (ACP) — Aurora, Colorado
- University of Colorado Cancer Center - Highlands Ranch Hospital — Highlands Ranch, Colorado
Phase 1, Phase 2 Recruiting Industry
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are. The second goal of thi…
Sponsor: BioNTech SE
NCT ID: NCT07186842
Sites in Colorado: - SCRI at HCA Health One — Denver, Colorado
Phase 2 Recruiting Academic/Other
Rectal cancer patients who do not achieve a complete response to standard of care chemotherapy and radiation often require surgical resection as part of curative intent therapy. This study will evaluate whether additional "focal" radiation…
Sponsor: University of Colorado, Denver
NCT ID: NCT07292298
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 1 Recruiting Industry
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker…
Sponsor: Hoffmann-La Roche
NCT ID: NCT04929223
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
- Rocky Mountain Cancer Centers, LLP — Lone Tree, Colorado